Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

The randomised trial saw over half of patients dosed with Sunosi were able to achieve clinical response to the therapy ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention ...

March 25 (Reuters) - Axsome Therapeutics' (AXSM.O), opens new tab experimental drug to treat attention deficit hyperactivity disorder (ADHD) helped improve symptoms of the developmental disorder ...

Investing.com -- Shares of Axsome Therapeutics (NASDAQ: AXSM) fell 5.5% following the announcement of its phase 3 trial results for Solriamfetol in adults with ADHD, which achieved its primary ...

Axsome Therapeutics AXSM announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD), has met its primary and key ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Axsome Therapeutics’ Phase III Focus trial investigating its attention-deficit hyperactivity disorder (ADHD) therapy, Sunosi (solriamfetol), has met its primary endpoint and provided a ...